AzTrials
AzTrials

Panic Attacks and DisordersIEPDNCT06073691

Interoceptive Exposure in Panic Disorder

A study testing Exercise intervention in people with Panic Attacks and Disorders, run by University of Sao Paulo General Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to test action exercises in the treatment of people with a diagnosis of Panic disorders with or without agoraphobia. The main question it aims to answer is: To investigate the feasibility and effectiveness of a Panic Disorder (PD) treatment protocol based on anaerobic exercise as an… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Panic Attacks and Disorders
What is being tested?
Exercise intervention
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
72 participants
Where
No sites listed yet
Study dates
1 Jul 2015to 1 Dec 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Diagnosis of PD with or without agoraphobia, based on the Mini International Neuropsychiatric Interview (MINI) and in accordance with the Diagnostic and Statistical Manual of mental disorders number 4 (DSM-IV) criteria;
  • No undergoing medical or other treatments for at least 12 weeks.

Who cannot join

  • Clinically relevant risk of cardiovascular disease (according to the Physical Activity Readiness Questionnaire - PAR-Q scale);
  • Practice of regular physical exercise for ≥ 150 minutes per week;
  • History or current substance abuse or dependence;
  • Pregnancy;
  • Breastfeeding;
  • Clinically relevant suicidal ideation or previous suicide attempts.

About this study

Official title: Intermittent Anaerobic Exercise as Interoceptive Exposure Strategy in the Treatment of Patients With Panic Disorder: Randomized Clinical Trial

The goal of this clinical trial is to test action exercises in the treatment of people with a diagnosis of Panic disorders with or without agoraphobia.

The main question it aims to answer is:

Read more

To investigate the feasibility and effectiveness of a Panic Disorder (PD) treatment protocol based on anaerobic exercise as an interoceptive exposure therapy.

Participants will The participants were randomly allocated to a 12-week program of either Intermittent Anaerobic Exercise.

Researchers will compare two groups, one with treatment through an intermittent aerobic exercise (IAE) protocol and the other group with treatment via a muscle relaxation protocol (RT), to see if there is feasibility and efficacy of a Panic Disorder treatment protocol based on anaerobic exercise as exposure therapy, compared to a relaxation activity.

Read the detailed description

Study design

The present study compared the effectiveness of two interventions for the treatment of PD:

  1. Intermittent Anaerobic Exercise (IAE), performed as a regular and controlled systematic physical exercise of running and walking to provide Interoceptive Exposure (IE);
  2. Jacobson's Progressive Muscle Relaxation method (RT). The study was designed as a prospective, two-arm, blinded, randomized, controlled clinical trial. Patients and assessors were informed that participants could receive an active pharmacological treatment or a matching placebo; however, all patients received only a placebo. The study was carried out at the Anxiety Disorders Program of the Institute of Psychiatry and the Institute of Orthopedics and Traumatology of the Faculty of Medicine of the University of São Paulo, São Paulo, Brazil.

Subjects The subjects were referred for treatment to the Anxiety Disorder Program at the emergency room (PS) of the Heart Institute (InCor). After clinical interviews of 121 suitable individuals, it was discovered that 102 met the pre-established inclusion criteria.

Participants were randomly allocated a Microsoft Excel spreadsheet to a 12-week program of IAE (n = 51) or RT (n = 51). Seventy-two patients completed the study, 38 women (52.8%) and 34 men (47.2%), aged between 21 and 51 years (mean: 33.3 ± 7.7 years). Among them, 22 (30.6%) were smokers. The mean age of onset of panic attacks was 28.3 ± 4.5 years. These groups were not significantly different in terms of sociodemographic characteristics.

Cardiovascular status assessments Initially, the subjects performed an exercise test on a medical treadmill at different speeds and inclines. As a subjective criterion, the Borg Rating of Perceived Exertion (RPE) scale was used in all tests paired with exercise intensity monitoring. However, in patients with PD, a simple assessment of subjective perception of exertion, such as the Borg RPE scale, may be insufficient to accurately capture the intensity of physical exertion. Before the test, the Physical Activity Readiness Questionnaire (PAR-Q) was used for cardiovascular risk, although the Heck test protocol presents a minimal risk of cardiac events (1/10,000-1/20,000).

Outcome evaluations The study evaluator was a trained psychiatrist with experience in using the MINI questionnaire and the rating scales used in this project. He was unaware of the patient's allocation and performed all assessments. All patients were evaluated at presentation (week -2), at baseline (week 0), and at weeks 6, 12, and 24 follow-up assessment (FU). Intervention programs were carried out weekly from week 0 to week 12.

The activities began with a short stretching session, and a warm-up, following the specificity of the exercise, of approximately 5 minutes at 55% of the individual's Maximum Heart Rate (Fcmax), previously stipulated by the exercise test (Ergospirometry).

After warming up, the patient walked for 15 minutes at 65% Fcmax. followed by a 30-second run at 85% Fcmax, returning to an active recovery of another 15 minutes of walking at 65% Fcmax, followed by another 5 minutes at 55% Fcmax, finishing with a stretch specific.

All participants had their heart rates monitored by a heart rate monitor. The time of anaerobic activity was gradually increased as a way of training this capacity and as a motivating factor for exercise.

The relaxation activities were led by a psychologist collaborating with the project. Three weekly sessions lasting 45 minutes were held. for three months. Relaxation followed criteria based on Progressive Muscle Relaxation Techniques.

The Jacobson technique can reduce or nullify the muscle tension found in anxious moments. The technique offers an easy way to identify muscles in tension and their relaxation, as most patients do not realize that the muscles are in tension.

The patient is placed in the supine position. Contract each muscle group or isolated muscle for 5 to 7 seconds and then relax for 20 to 30 seconds. The sequence is performed once, but when the region remains tense, the sequence is repeated up to 5 times. When relaxing, some verbal instructions were introduced to help with this, such as "throw away the tension", "feel calm and rested", "relax and soften your muscles" and "let the tension dissolve". The most important thing in the process was to make the patient notice the difference between muscle contraction and relaxation.

Primary outcome measure:

Changes in PD severity scores were assessed using the Panic Agoraphobia Scale (PAS), a 13-item measure of PD symptoms; Observer-rated and self-reported versions were used in the present study. The items assessed were panic attacks, agoraphobic avoidance, anticipatory anxiety, disability, functional impairment, and health concerns. The assessor was fluent in Portuguese and English and had copies of the assessed and self-reported PAS versions. The Portuguese version of the scale was translated from English by one of the authors during the scale development phase in agreement with the author.

Secondary outcome measures:

  1. Frequency and intensity of panic attacks, measured through a panic attack registry;
  2. Severity of general anxiety symptoms, assessed by the Hamilton Anxiety Rating Scale (HAM-A);
  3. Severity of depressive symptoms, assessed by the Hamilton Rating Scale for Depression (HAM-D).

Successful response to treatment was defined as a ≥ 50% reduction from baseline scores on both Hamilton scales.

Data analysis Pearson's chi-square test was used to analyze the distribution of categorical variables. The Shapiro-Wilk test and other distribution exploration techniques were used to assess whether the continuous variables followed a normal distribution. The Mann-Whitney-U test was used to compare continuous variables between intervention groups. Two-way repeated-measures ANOVA and post-hoc analysis for pairwise comparisons with Holm's correction were used to evaluate between- and within-group differences over time.

The sample size needed for 95% power was estimated to be 36 subjects per group using G*Power software v. 3.1.9.6 (available from the University of Dusseldorf). The data were analyzed and processed using Jamovi software v. 2.2.5. A significance level of 5% was considered in all analyses.

Being tested
Exercise intervention, Placebo
Keywords
aerobic exercise, physical activity, treatment, interoception, exposure therapy.
Medical subject headings
Panic Disorder, Disease, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercise interventionBehavioural

    Also called Interoceptive exposure therapy

    Practice systematic and regular aerobic physical exercise (walking and running).

  • PlaceboOther

    Placebo

Study groups in NCT06073691
Study groupRoleWhat they receive
Exercise interventionExperimentalOn each training day, the activity started with a 5-minute stretching and warm-up session; then, a 15-minute walk at 65% of the maximum heart rate (MHR), followed by a 30-second run at 85% MHR, and finally another 15-minute walk at 65% MHR. The running time was gradually increased in individualized and supervised sessions. The exercise intensity was predetermined based on the patient's baseline cardiopulmonary function, and the heart rates (HR) were assessed using a Polar RS300X heart rate monitor.
Receives: Behavioral: Exercise intervention
PlaceboPlacebo comparatorThe participants might receive an active pharmacological treatment or a matching placebo
Receives: Behavioral: Exercise intervention; Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PD severity scores

    The Panic Agoraphobia Scale scores

    Measured: 12 weeks of intervention

Secondary outcomes (2)
  1. Frequency of panic attacks

    The number of panic attacks per day

    Measured: 12 weeks of intervention

  2. Intensity of panic attacks

    Intensity measured on a scale of 0 to 5, where a higher number means a greater, more severe intensity of panic attack.

    Measured: 12 weeks of intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2023
  2. Study start1 Jul 2015
  3. Primary completion1 Jul 2016
  4. Study completion1 Dec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
The study was designed as a prospective, two-arms, blinded, randomized controlled clinical trial. Patients and evaluators were informed that the participants might receive an active pharmacological treatment or a matching placebo; however, all patients received only a placebo. The study was conducted at the Anxiety Disorder Program of the Institute of Psychiatry and at the Institute of Orthopaedics and Traumatology of the University of Sao Paulo Medical School, Sao Paulo, Brazil.
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
72 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06073691
Sponsor's protocol ID
IPq-HCFMUSP
Acronym
IEPD
Status last verified
Sep 2023
First submitted
20 Sep 2023
Last updated
10 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Muotri RW, Luciano AC, Garrudo Guirado A, Lotufo Neto F, Bernik M. Brief intermittent intense exercise as interoceptive exposure for panic disorder: a randomized controlled clinical trial. Front Psychiatry. 2026 Feb 9;16:1739639. doi: 10.3389/fpsyt.2025.1739639. eCollection 2025.

    PubMed 41737725

Questions about this trial

What is this clinical trial studying?

A study testing Exercise intervention in people with Panic Attacks and Disorders, run by University of Sao Paulo General Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PD severity scores (time frame: 12 weeks of intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06073691, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in